iData Insights

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 02, 2016 16:01 IST

This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179108/refractory-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179108/refractory-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8

Therapeutics Development 9

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 9

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17

Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20

Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21

4SC AG 21

AbbVie Inc. 22

Astellas Pharma Inc. 23

Astex Pharmaceuticals, Inc. 24

AstraZeneca Plc 25

Boehringer Ingelheim GmbH 26

Bristol-Myers Squibb Company 27

Celgene Corporation 28

Cellular Biomedicine Group, Inc. 29

F. Hoffmann-La Roche Ltd. 30

Hutchison MediPharma Limited 31

ImmunoGen, Inc. 32

Immunomedics, Inc. 33

Incyte Corporation 34

Infinity Pharmaceuticals, Inc. 35

Innate Pharma SA 36

Juno Therapeutics Inc. 37

Karyopharm Therapeutics, Inc. 38

Les Laboratoires Servier SAS 39

LFB S.A. 40

Lymphocyte Activation Technologies, S.A. 41

Medicenna Therapeutics, Inc 42

MedImmune, LLC 43

Millennium Pharmaceuticals, Inc. 44

MorphoSys AG 45

Novartis AG 46

Ono Pharmaceutical Co., Ltd. 47

Portola Pharmaceuticals, Inc. 48

Sanofi 49

TG Therapeutics, Inc. 50

Threshold Pharmaceuticals, Inc. 51

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Combination Products 53

Assessment by Target 54

Assessment by Mechanism of Action 57

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

(INCB-039110 + INCB-040093) - Drug Profile 64

4SC-202 - Drug Profile 65

acalabrutinib - Drug Profile 67

ACP-319 - Drug Profile 70

afuresertib hydrochloride - Drug Profile 71

AGS-67E - Drug Profile 73

AT-7519 - Drug Profile 74

AZD-6738 - Drug Profile 77

BI-836826 - Drug Profile 79

BMS-986016 - Drug Profile 80

buparlisib hydrochloride - Drug Profile 81

CBM-C19.1 - Drug Profile 85

CBM-C20.1 - Drug Profile 86

CC-122 - Drug Profile 88

Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 90

Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 91

cerdulatinib - Drug Profile 92

duvelisib - Drug Profile 93

evofosfamide - Drug Profile 96

HMPL-523 - Drug Profile 104

IMGN-529 - Drug Profile 105

IMMU-114 - Drug Profile 107

inebilizumab + rituximab - Drug Profile 108

IPH-2201 - Drug Profile 109

JCAR-014 - Drug Profile 111

JCAR-015 - Drug Profile 112

lirilumab - Drug Profile 114

MDNA-56 - Drug Profile 116

MOR-208 - Drug Profile 117

nivolumab - Drug Profile 119

obinutuzumab - Drug Profile 126

pilaralisib - Drug Profile 129

S-055746 - Drug Profile 132

selinexor - Drug Profile 133

spebrutinib besylate - Drug Profile 138

TAK-659 - Drug Profile 140

TGR-1202 - Drug Profile 141

tisagenlecleucel-T - Drug Profile 143

trametinib dimethyl sulfoxide - Drug Profile 146

ublituximab - Drug Profile 149

ublituximab + TGR-1202 - Drug Profile 151

UC-961 - Drug Profile 152

ulocuplumab - Drug Profile 153

urelumab - Drug Profile 155

venetoclax - Drug Profile 157

Refractory Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 160

Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 248

Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 249

Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 250

Featured News & Press Releases 250

Appendix 259

Methodology 259

Coverage 259

Secondary Research 259

Primary Research 259

Expert Panel Validation 259

Contact Us 259

Disclaimer 260" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8

Therapeutics Development 9

Read More http://www.idatainsights.com/reports-landing-page.php?id=179108/refractory-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.